

UC Santa Barbara

UC Santa Barbara Previously Published Works

Title

PSEN1 E280A Cholinergic-like Neurons and Cerebral Spheroids Derived from Mesenchymal Stromal Cells and from Induced Pluripotent Stem Cells Are Neuropathologically Equivalent.

Permalink

<https://escholarship.org/uc/item/4769h3qf>

Journal

International Journal of Molecular Sciences, 24(10)

Authors

Mendivil-Perez, Miguel

Velez-Pardo, Carlos

Lopera, Francisco

et al.

Publication Date

2023-05-18

DOI

10.3390/ijms24108957

Peer reviewed



Article

PSEN1 E280A Cholinergic-like Neurons and Cerebral Spheroids Derived from Mesenchymal Stromal Cells and from Induced Pluripotent Stem Cells Are Neuropathologically Equivalent

Miguel Mendivil-Perez ^{1,†}, Carlos Velez-Pardo ^{1,†}, Francisco Lopera ¹, Kenneth S. Kosik ²
and Marlene Jimenez-Del-Rio ^{1,*}

¹ Neuroscience Research Group, Medical Research Institute, Faculty of Medicine, University of Antioquia (UdeA), Calle 70 No. 52-21, Calle 62#52-59, Building 1, Room 412, SIU, Medellin 050010, Colombia; miguel.mendivil@udea.edu.co (M.M.-P.); calberto.velez@udea.edu.co (C.V.-P.); francisco.lopera@gna.org.co (F.L.)

² Neuroscience Research Institute, Department of Molecular Cellular Developmental Biology, University of California, Santa Barbara, CA 93106, USA; kenneth.kosik@lifesci.ucsb.edu

* Correspondence: marlene.jimenez@udea.edu.co

† These authors contributed equally to this work.

Abstract: Alzheimer's disease (AD) is a chronic neurological condition characterized by the severe loss of cholinergic neurons. Currently, the incomplete understanding of the loss of neurons has prevented curative treatments for familial AD (FAD). Therefore, modeling FAD in vitro is essential for studying cholinergic vulnerability. Moreover, to expedite the discovery of disease-modifying therapies that delay the onset and slow the progression of AD, we depend on trustworthy disease models. Although highly informative, induced pluripotent stem cell (iPSCs)-derived cholinergic neurons (ChNs) are time-consuming, not cost-effective, and labor-intensive. Other sources for AD modeling are urgently needed. Wild-type and presenilin (PSEN1) p.E280A fibroblast-derived iPSCs, menstrual blood-derived menstrual stromal cells (MenSCs), and umbilical cord-derived Wharton Jelly's mesenchymal stromal cells (WJ-MSCs) were cultured in *Cholinergic-N-Run* and *Fast-N-Spheres V2* medium to obtain WT and PSEN 1 E280A cholinergic-like neurons (ChLNs, 2D) and cerebroid spheroids (CSs, 3D), respectively, and to evaluate whether ChLNs/CSs can reproduce FAD pathology. We found that irrespective of tissue source, ChLNs/CSs successfully recapitulated the AD phenotype. PSEN 1 E280A ChLNs/CSs show accumulation of iAPP β fragments, produce eA β 42, present TAU phosphorylation, display OS markers (e.g., oxDJ-1, p-JUN), show loss of $\Delta\Psi_m$, exhibit cell death markers (e.g., TP53, PUMA, CASP3), and demonstrate dysfunctional Ca²⁺ influx response to ACh stimuli. However, PSEN 1 E280A 2D and 3D cells derived from MenSCs and WJ-MSCs can reproduce FAD neuropathology more efficiently and faster (11 days) than ChLNs derived from mutant iPSCs (35 days). Mechanistically, MenSCs and WJ-MSCs are equivalent cell types to iPSCs for reproducing FAD in vitro.

Keywords: Alzheimer; apoptosis; E280a; iPSCs; presenilin; mutant; mesenchymal stromal



Citation: Mendivil-Perez, M.; Velez-Pardo, C.; Lopera, F.; Kosik, K.S.; Jimenez-Del-Rio, M. PSEN1 E280A Cholinergic-like Neurons and Cerebral Spheroids Derived from Mesenchymal Stromal Cells and from Induced Pluripotent Stem Cells Are Neuropathologically Equivalent. *Int. J. Mol. Sci.* **2023**, *24*, 8957. <https://doi.org/10.3390/ijms24108957>

Academic Editor: Xavier Morató

Received: 11 April 2023

Revised: 11 May 2023

Accepted: 13 May 2023

Published: 18 May 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Alzheimer's disease (AD) is a progressive and chronic neurological condition characterized by loss of memory due to vulnerability and the severe loss of cholinergic neurons from the nucleus basalis magnocellular of Meynert and cholinergic projections to the cortex and hippocampus [1,2]. AD is biologically described not only by the intracellular accumulation of amyloid-beta (iA β), extracellular amyloid- β (eA β)-containing plaques, and intracellular hyperphosphorylated tau-containing neurofibrillary tangles [3], but also by dysfunction in the highly interrelated endosomal and lysosomal clearance pathways

and loss of synaptic homeostasis [4]. However, it is not yet clear how iA β and/or eA β might signal cell death in AD [5]. Therefore, the incomplete understanding of the loss of cholinergic neurons has prevented curative treatments for AD [6]. This situation is even further aggravated by the appearance of early-onset familial AD (FAD) caused by mutations in one or more of at least three genes known as amyloid-beta precursor protein (APP), presenilin 1 (PSEN 1), and presenilin 2 (PSEN2) (<https://www.alzforum.org/mutations>, accessed on 7 May 2023). Specifically, most mutations in the PSEN1 gene, which codes for the catalytic component of γ -secretase responsible for APP processing [7,8], result in the overproduction of A β e.g., the 42-amino acid A β isoform [9]. Interestingly, the Glu280Ala (p. E280A, c.839A > C, exon 8) mutation in PSEN 1 is by far the most common and well-characterized causative mutation of FAD, affecting a large population localized in Antioquia, Colombia ([10]; <https://www.alzforum.org/mutations/pesen1-e280a-paisa>, accessed on 7 May 2023). Unfortunately, despite several efforts [11,12], there are no efficient therapies against PSEN 1 E280A FAD. These insidious outcomes have encouraged us, and others, to model the PSEN 1 FAD in vitro.

Modeling FAD with the induction of somatic cells (e.g., fibroblasts) into stem cells (e.g., human induced pluripotent stem cells, hiPSCs) has provided an important biological tool to potentially recreate the neuropathology of the disorder [13]. Indeed, several groups have generated PSEN 1 mutant iPSCs-derived neuronal cells that exhibit elevated A β 42 generation and increased TAU phosphorylation (e.g., [14–16]). Remarkably, an iPSC line derived from a patient with early-onset disease carrying the E280A mutation in the PSEN 1 gene was created [17]. Furthermore, the mutation was introduced into an iPSC line from a healthy individual using the CRISPR-Cas9 technology [18]. Although PSEN 1 E280A iPSCs-derived neurons produce increased levels of eA β 42 [19], no data are available to determine whether mutant iPSCs-derived neurons also display other typical neuropathological hallmarks of FAD, such as accumulation of iA β , oxidative stress (OS), and neuronal cell death markers, as well as TAU phosphorylation (p-TAU).

Obtaining iPSCs from patients bearing PSEN1 mutations is appealing; however, the isolation and purification procedures are technically challenging, expensive, time-consuming, and labor-intensive. Furthermore, the protocol for the differentiation of iPSCs into neuronal progenitor cells (NPCs), which can subsequently be patterned to different neuronal lineages, such as cholinergic, is time consuming, taking at least 35 days [20]. Alternatively, human mesenchymal stromal (stem) cells (MSCs) derived from menstrual blood (MenB) and Wharton's jelly tissue (WJ) might be easier to obtain, less expensive, and ready-to-use [21–24]. The MSCs are multipotent cells that can transdifferentiate into ectodermal lineage cells, such as oligodendrocyte progenitor-like cells [25], nerve-like cells [26], and cholinergic-like neurons [27,28], among others. Indeed, by using the *Cholinergic-N-Run* and *Fast-N-Spheres V2* mediums, we have recreated the molecular pathogenesis of PSEN1 E280A mutation FAD in planar (2D) ChLNs derived from umbilical-cord WJ-MSCs [29] and in 3D (cerebral spheroids) derived from menstrual mesenchymal stromal cells (MenSCs) [30]. The PSEN1 E280A ChLNs and CSs exhibit: (i) early intracellular accumulation of A β PP fragments (iA β PPf, but not A β 42 peptide); (ii) early oxidized DJ-1 at residue Cys¹⁰⁶SO₃, indicative of OS; (iii) elevated p-TAU; (iv) loss of the mitochondrial membrane potential ($\Delta\Psi_m$), (v) displayed cell death markers such as activation of caspase 3 (CASP3), and DNA fragmentation; (vi) generated high amounts of eA β 42; and (vii) showed Ca²⁺ influx alteration in response to acetylcholine (ACh) stimuli compared to wild-type ChLNs and CSs [29,30]. These findings in ChLNs and CSs show great promise for modeling human FAD in vitro for regenerative medicine and identifying therapeutic treatments for AD.

The aim of the present study was to determine whether 2D and 3D MenSCs- and umbilical-cord Wharton Jelly's MSCs-derived PSEN1 E280A ChLNs and CSs were neuropathologically equivalent to PSEN1 E280A ChLNs and CSs resulting from iPSC-derived neural progenitor cells. Therefore, accumulation of iA β 42, production of eA β 42, phosphorylation TAU, presence of OS makers (e.g., oxDJ-1, p-JUN), loss of $\Delta\Psi_m$, cell death markers (e.g., TP53, PUMA, CASP3), and Ca²⁺ influx response to ACh were assessed in PSEN1

E280A ChLNs and CSs derived from iPSCs, MenSCs, and WJ-MSCs. We demonstrate for the first time that FAD PSEN1 E280A pathology can be recapitulated in WJ-MSC- and MenSCs-derived ChLNs and CSs in about 11 days, similar to PSEN1 E280A ChLNs derived from iPSCs-NPC in 35 days.

2. Results

2.1. Wild-Type and PSEN1 E280A MenSCs, and WJ-MSCs Express Comparable Cellular Pluripotential Markers as iPSCs

We wanted to first confirm that wild-type (WT) and mutant iPSCs, MenSCs, and WJ-MSCs displayed typical cellular pluripotential markers. As shown in Figure 1, WT (Figure 1A) and PSEN1 E280A iPSCs (Figure 1B), MenSCs (Figure 1C,D), and WJ-MSCs (Figure 1E,F) expressed not only the pluripotent transcription factor octamer binding transcription factor 4 (OCT4, Figure 1A–F), but also the transcription factor Sex determining Region Y-box 2 (SOX 2, Figure 1G–L), Homeobox transcription factor Nanog (NANOG, Figure 1M–R), and Krüppel-like factor 2 (KLF, Figure 1S–X), which are essential for pluripotency and self-renewal of stem cells (Figure 1Y,Z,AA,AB). As expected, WT and PSEN1 E280A iPSCs, MenSCs, and WJ-MSCs differentiated into mesoderm (Figure 1AC–AH), and ectoderm (Figure 1AI–AN) germinal layers during embryonic development according to the presence of vimentin and Nestin markers, respectively; however, the endoderm layer was only present in iPSCs (Figure 1AO–AP) but absent in both WT and mutant MenSCs and WJ-MSCs (Figure 1AQ–AT) according to the endodermal marker C-X-C chemokine receptor type 4 (CXCR4), which is a specific marker for stromal-derived-factor-1.




Figure 1. Cont.




Figure 1. Determination of pluripotency markers by immunofluorescence. Nuclear colocalization of OCT4 in WT (A–A'') and PSEN1 E280A (B–B'') iPSCs, in WT (C) and PSEN1 E280A MenSCs (D), and in WT (E) and PSEN1E280A WJ-MSCs (F). Colocalization of SOX2 in WT (G–G'') and PSEN 1 E280A iPSCs (H–H''), in WT (I) and PSEN 1 E280A MenSCs (J), and in WT (K) and PSEN 1E280A WJ-MSCs (L). Colocalization of Nanog in WT (M–M'') and PSEN 1 E280A iPSCs (N–N''), in WT (O) and PSEN 1 E280A MenSCs (P), and in WT (Q) and PSEN 1 E280A WJ-MSCs (R). Colocalization of Klf4 in WT (S–S'') and PSEN 1 E280A iPSCs (T–T''), in WT (U) and PSEN 1 E280A MenSCs (V), and in WT (W) and PSEN 1 E280A WJ-MSCs (X). Quantitative data showing the nuclear mean fluorescence intensity for OCT4 (Y), SOX2 (Z), NANOG (AA), and KLF4 (AB). The figures represent one out of three independent experiments. The data are expressed as the mean \pm SD; significant values were determined by one-way ANOVA with Tukey's post hoc test; ns: not significant. Image magnification, 20 \times . Representative immunocytochemistry images of mesoderm germ layer stained for Vimentin (AC–AH), ectoderm stained for Nestin (AI–AN), and endoderm stained for CXCR4 (AO–AT) in WT and PSEN 1 E280 A mutation from iPSCs, MenScs, and WJ-MSCs. Nuclei are stained with Hoechst (blue). Scale bars 25 μ m.

2.2. Wild-Type and PSEN 1 E280A MenSCs and WJ-MSCs Express Neuronal Stem Markers as iPSC-Derived NPC

We initially generated WT and PSEN 1 E280A iPSC-derived neural progenitor cells (NPC) using a well-established stepwise protocol lasting 27 days (Figure 2A,B). The iPSCs (Figure 2C,D) were successively exposed to different culture formulae (Section 4) to obtain embryonic bodies (EB, Figure 2E,F), pre-NPC (Figure 2G,H), and NPC (Figure 2I,J). No evident morphological differences were observed between WT and mutant cells at the different stages of cellular differentiation process (Figure 2C,E,G,I versus Figure 2D,F,H,J).

Then, we evaluated whether WT and PSEN 1 E280A iPSC-derived NPC, MenSCs, and WJ-MSCs expressed neuronal stemness protein markers. Effectively, iPSC-derived NPCs (Figure 3A,B), MenSCs (Figure 3C,D), and WJ-MSCs (Figure 3E,F) expressed SOX2 and Nestin (Figure 3G,H).




Figure 2. Schematic representation of the iPSCs differentiation protocol: (A,B) graphic timeline of iPSC-derived NPC, cholinergic neurons (ChLNs), or cerebral spheroids (CSs); (C,D) iPSC colony morphology from WT and PSEN1 E280A cells; (E,F) embryoid body (EB) morphology from WT and PSEN1 E280A cells; (G,H) pre-NPC morphology from WT and PSEN1 E280A cells; and (I,J) NPC morphology from WT and PSEN1 E280A cells.

2.3. WT and PSEN 1 E280A MenSCs and WJ-MSCs Can Transdifferentiate into ChLNs and CSs Similarly to iPSC-Derived NPC

We further cultured WT and mutant iPSC-induced NPC (Figure 4A,B), MenSCs (Figure 4C,D), and WJ-MSCs (Figure 4E,F) in *Cholinergic-N-Run* (Figures 2A and 4G) to obtain cholinergic-like neurons (ChLNs, Figure 4H–M), and assessed them by flow cytometry analysis (Figure 4N–P) and immunofluorescence microscopy (Figure 4Q–Y). The highest percentage of ChLNs was obtained from both WT and mutant WJ-MSCs (Figure 4P), whereas iPSCs (Figure 4N) and MenSCs (Figure 4O) showed no difference. Similar observations were recorded by immunofluorescent microscopy (Figure 4Q–Y).

When the NPC (obtained at day 27) and MSCs were exposed to *Fast-N-Spheres V2* medium (Figures 2B and 5A), cerebral spheroids (CSs) were clearly identified (Figure 5B–G) in a process that lasted eight additional days and only 11 days for MenSCs and for WJ-

MSCs. To further verify the cholinergic phenotype in the CSs, WT and mutant MenSCs-, WJ-MSCs-, and NPC-derived cholinergic cells were assessed for expression of neuronal markers. Figure 5 shows co-expression of the neuronal marker ChAT/VACHT/ β III tubulin detected in NPCs-derived CSs (Figure 5H,I), MenSCs-derived CSs (Figure 5J,K), and WJ-MSCs-derived CSs (Figure 5L,M), showing that mutant cells express less β III tubulin (Figure 5N) and ChAT (Figure 5P) compared to WT, but no difference was found in the expression of VACHT (Figure 5O).




Figure 3. Determination of NPC markers by immunofluorescence. iPSCs were differentiated into NPCs as described in Section 4. Then, Nestin (A',B'), SOX2 (A'',B'') proteins, and nuclei (A''',B''') were simultaneously identified in WT (A) and PSEN1 E280A (B) cells. MenSCs were cultured in regular MSC medium, then cells were stained to identify Nestin, SOX2 proteins, and nuclei in WT (C) and PSEN1 E280A (D) cells. WJ-MSCs were cultured in regular MSC medium, then cells were stained to identify Nestin, SOX2 proteins, and nuclei in WT (E) and PSEN1 E280A (F) cells. Quantitative data showing the mean fluorescence intensity for cytosolic Nestin (G), and SOX2 (H). The figures represent one out of three independent experiments. The data are expressed as the mean \pm SD; significant values were determined by one-way ANOVA with Tukey's post hoc test; ns: not significant. Image magnification, 20 \times .




Figure 4. The iPSCs-, MenSCs-, and WJ-MSCs-derived cholinergic-like neurons (ChLNs): (A–F) light microscopy pictures of WT (A) and PSEN 1 E280A iPSC-derived NPC (B); undifferentiated WT (C) and mutant MenSCs (D); and undifferentiated WT (E) and mutant WJ-MSCs (F). Graphic timeline of WT and PSEN 1 E280A MenSCs- and WJ-MSCs-derived cholinergic-like neurons (ChLNs) (G); light microscopy pictures of WT (H) and PSEN 1 E280A iPSCs::NPC-derived ChLNs (I); WT (J) and mutant MenSCs-derived ChLNs (K), and WT (L) and mutant WJ-MSCs-derived ChLNs (M). Flow cytometry analysis of WT and PSEN 1 E280A iPSCs::NPC- (N), MenSCs- (O), and WJ-MSCs-derived ChLNs (P) to identify VACHT and ChAT. The histograms represent 1 out of 3 independent experiments. The data are expressed as the mean ± SD; significant values were determined by one-way ANOVA with Tukey’s post hoc test; ns = not significant. Representative fluorescence microscopy pictures of WT (Q)

and PSEN 1 E280A NPC-derived ChLNs (R), WT (S) and mutant MenSCs-derived ChLNs (T), and WT (U) and mutant WJ-MSCs-derived ChLNs (V) stained with antibodies against ChAT (Q',R',S-V), VAcHT (Q'',R'',S-V), and β III Tubulin (Q''',R''',S-V). Quantitative data showing the mean fluorescence intensity for β III Tubulin (W), VAcHT (X), and ChAT (Y). The figures represent 1 out of 3 independent experiments. The data are expressed as the mean \pm SD; significant values were determined by one-way ANOVA with Tukey's post hoc test; Image magnification, 20 \times .




Figure 5. The iPSCs-, MenSCs-, and WJ-MSCs-derived cerebral spheroids (CSs) express cholinergic markers: (A) graphic timeline of WT and PSEN 1 E280A MenSCs- and WJ-MSCs-derived cerebral spheroids (CSs); (B–G) light microscopy pictures of WT (B) and PSEN 1 E280A iPSCs::NPC-derived CSs (C), WT (D) and mutant MenSCs-derived CSs (E), and WT (F) and mutant WJ-MSCs-derived CSs (F). Representative fluorescence microscopy pictures of WT (H) and PSEN 1 E280A NPC-derived CSs (I), WT (J) and mutant MenSCs-derived CSs (K), and WT (L) and mutant WJ-MSCs-derived CSs (M) stained with antibodies against ChAT (H',I',J–M), VAcHT (H'',I'',J–M), and β III tubulin (H''',I''',J–M). Quantitative data showing the mean fluorescence intensity for β III Tubulin (N), VAcHT (O), and ChAT (P). The figures represent 1 out of 3 independent experiments. The data are expressed as the mean \pm SD; significant values were determined by one-way ANOVA with Tukey's post hoc test; * $p < 0.05$; ** $p < 0.005$; *** $p < 0.001$. ns: not significant. Image magnification, 20 \times .

2.4. PSEN 1 E280A ChLNs Derived from MenSCs and WJ-MSCs Display Typical iAPP β f, p-Tau, and Oxidative Stress (oxDJ-1) Markers as Mutant NPC-Derived ChLNs

Based on the above observations, NPC-, MenSCs-, and WJ-MSCs-derived ChLNs were further evaluated for early accumulation of iAPP β f, p-Tau, and oxidized DJ-1, as evidence of OS. As shown in Figure 6, all three WT cellular sources show no detectable accumulation of iAPP β f (Figure 6A',B,C), oxDJ-1 (e.g., Figure 6A'',B,C), nor p-Tau (Figure 6G',H,I). In contrast, mutant ChLNs derived from MenSCs, WJ-MSCs, and NPC express abundant accumulation of iAPP β f (Figure 6D',E,F), ox DJ-1 (Figure 6D'',E,F), and p-Tau (Figure 6J',K,L). Statistical analysis revealed significant differences between WT and PSEN 1 E280A in production of iAPP β f (Figure 6M), ox DJ-1 (Figure 6N), and p-TAU (Figure 6O) compared to WT. PSEN 1 E280A WJ-MSCs-derived ChLNs generated the highest amount of iAPP β f, but MenSCs-derived ChLNs showed the highest amount of ox DJ-1. No statistically significant differences were found in p-Tau from the ChLNs. Similar data were obtained by flow cytometry analysis (Figure 6P–U).

Further analysis shows that the $\Delta\Psi_m$ in ChLNs derived from WT PSEN 1 NPCs (Figure 7A,A'), MenSCs (Figure 7D,D'), and WJ-MSCs (Figure 7G,G') was unaffected when compared to PSEN 1 E280A ChLNs (Figure 7B,B',E,E',H,H'), which presented a marked loss of $\Delta\Psi_m$ (Figure 7C,F,I). When the generation of ROS (e.g., H₂O₂) was examined according to dichlorofluorescein (DCF)-positive cells, there were significantly more DCF+ cells in mutant ChLNs from the three cellular sources than WT ChLNs (Figure 7C,F,I). The loss of $\Delta\Psi_m$ and generation of ROS (H₂O₂) were found to be similar in mutant ChLNs from any source.

2.5. PSEN 1 E280A ChLNs Derived from MenSCs, and WJ-MSCs Show Cell Death Markers of Apoptosis as Mutant NPC-Derived ChLNs

Next, we evaluated whether mutant ChLNs express apoptosis markers. Figure 8 shows that the protein PUMA was constitutively expressed at low levels in WT ChLNs derived from NPC (Figure 8A,A'), MenSCs (Figure 8B), and WJ-MSCs (Figure 8C,M). In contrast, PUMA showed a statistically significant increase in PSEN 1 E280A ChLNs from the three cellular sources (Figure 8D,D',E,F) with almost similar strength (Figure 8M). Although almost no basal expression of p-JUN (Figure 8A,A'',B,C,N), TP53 (Figure 8G,G',H,I,O), and CASP3 (Figure 8G,G'',H,I,P) was detected in WT ChLNs, these proteins showed a statistically significant rise in PSEN 1 E280A ChLNs from NPC (Figure 8D,D'',J,J',J'',N–P), MenSCs (Figure 8E,K,N–P), and WJ-MSCs (Figure 8F,L,N–P). Similar data were obtained by flow cytometry analysis (Figure 8Q–V).

2.6. PSEN 1 E280A ChLNs Derived from NPC, MenSC and WJ-MSCs Do Not Respond to Acetylcholine (ACh) Stimuli

To evaluate whether ChLNs derived from NPCs, MenSCs, and WJ-MSCs were responsive to neurotransmitter stimuli as an assessment of cholinergic neuronal functionality, the WT and mutant ChLNs were exposed to acetylcholine (ACh), and Ca²⁺ influx was recorded in fluorescent microscopy. As shown in Figure 9, ACh induced a comparable transient elevation of intracellular Ca²⁺ in WT ChLNs derived from NPC (Figure 9A), MenSCs (Figure 9D), and WJ-MSCs (Figure 9G) with an average fluorescence change (DF/F) of 3.8 ± 0.6 -fold, and a mean duration of 40 ± 10 s (n = 20 ChLN cells imaged, N = 3 dishes/each cell source) according to cytoplasmic Ca²⁺ response to Fluo-3-mediated imaging (Figure 9C,F,I). Remarkably, PSEN 1 E280A ChLNs obtained from the three cellular sources almost did not respond to ACh (Figure 9B,C,E,F,H,I).




Figure 6. Determination of Alzheimer’s pathological proteins in ChLNs. Representative immunofluorescence microscopy of WT (A–C,G–I) and PSEN 1 E280A iPSCs::NPC-, MenSCs-, and JW-MSCs-derived ChLNs (D–F,J–L) stained to identify iAPPβf (A’,D’,B,C,E,F), ox-DJ-1 (A’’,D’’,B,C,E,F), p-TAU (G’,J’,H–K), t-Tau (G’’,J’’,H–K), and nuclei (A’’’,D’’’,B,C,E,F,H–L). Quantitative data showing the mean fluorescence intensity for iAPPβf (M), ox-DJ-1 (N), and the p-TAU/t-TAU ratio (O). The

figures represent 1 out of 3 independent experiments. The data are expressed as the mean \pm SD; significant values were determined by one-way ANOVA with Tukey's post hoc test; * $p < 0.05$; ** $p < 0.005$; *** $p < 0.001$. Image magnification, 20 \times . Flow cytometry analysis of WT and PSEN 1 E280A iPSCs::NPC- (P,S), MenSCs- (Q,T), and WJ-MSCs-derived ChLNs (R,U) to identify iAPP β f (P-R), ox-DJ-1 (P-R), and p-Tau (S-U). The histograms represent 1 out of 3 independent experiments. The data are expressed as the mean \pm SD; significant values were determined by one-way ANOVA with Tukey's post hoc test; ** $p < 0.005$; *** $p < 0.001$.




Figure 7. Evaluation of mitochondrial membrane potential ($\Delta\Psi_m$) and ROS production in ChLNs. At day 35, WT and PSEN 1 E280A iPSCs::NPC-derived ChLNs (A–C), and at day 11, WT and PSEN 1 E280A MenSCs (D–F), and WT and PSEN 1 E280A WJ-MSCs-derived ChLNs (G–I) were stained with Hoechst, red Mitotracker, and dichlorofluorescein to identify nuclei, $\Delta\Psi_m$ and ROS production. Images were analyzed, and quantitative data were compared (C,F,I). The figures represent one out of three independent experiments. The data are expressed as the mean \pm SD; significant values were determined by one-way ANOVA with Tukey's post hoc test; ** $p < 0.005$; *** $p < 0.001$. Image magnification 20 \times . White square area is magnified inset (A',B',D',E',G',H'), magnification 100 \times .




Figure 8. Determination of apoptosis-associated proteins in ChLNs. Representative immunofluorescence microscopy of WT (A–C,G–I) and PSEN 1 E280A iPSCs::NPC- (D,J), MenSCs- (E,K), and JW-MSCs-derived ChLNs (F,L) stained to identify PUMA (A',D',B,C,E,F), p-JUN (A'',D'',B,C,E,F), TP53 (G',J',H–K), CASP3 (G'',J'',H–K), and nuclei (A''',D''',B,C,E,F,H–L). Quantitative data showing the mean fluorescence intensity for PUMA (M), c-JUN (N), TP53 (O), and CASP3 (P). The figures represent 1 out of 3 independent experiments. The data are expressed as the mean ± SD; significant values were determined by one-way ANOVA with Tukey's post hoc test; *** $p < 0.001$. Image magnification, 20×. Flow cytometry analysis of WT and PSEN 1 E280A iPSCs::NPC- (Q,T), MenSCs- (R,U), and WJ-MSCs-derived ChLNs (S,V) to identify PUMA (Q–S), p-JUN (Q–S), TP53 (T–V), and CASP3 (T–V). The histograms represent 1 out of 3 independent experiments. The data are expressed as the mean ± SD; significant values were determined by one-way ANOVA with Tukey's post hoc test; *** $p < 0.001$.




Figure 9. Evaluation of Acetylcholine (ACh) response. Time-lapse images (0, 10, 20, 30, and 40 s) of Ca^{2+} fluorescence in WT and E280A iPSC-derived neurons after 31 and 35 days ($n = 3$ dishes) as a response to ACh treatment (A,B,D,E). Time-lapse images (0, 10, 20, 30, and 40 s) of Ca^{2+} fluorescence in PSEN 1 WT and E280A MenSCs- and WJ-MSCs- derived ChLNs after 11 days ($n = 3$ dishes) as a response to ACh treatment (G,H) ACh was puffed into the culture at 0 s (arrow). Then, the Ca^{2+} fluorescence of cells was monitored at the indicated times. Color contrast indicates fluorescence intensity: dark blue < light blue < green < yellow < red. (C,F,I) Normalized mean fluorescence signal ($\Delta F/F$) over time, indicating temporal cytoplasmic Ca^{2+} elevation in response to ACh treatment in PSEN 1 WT and E280A cells. The data are expressed as the mean \pm SD; significant values were determined by one-way ANOVA with Tukey's post hoc test; * $p < 0.05$; ** $p < 0.005$; *** $p < 0.001$. Image magnification, 20 \times .

2.7. PSEN1 E280A ChLNs Derived from WJ-MSCs Secrete Higher Amount of Extracellular $\text{A}\beta_{42}$ Than Mutant ChLNs Derived from NPC and MenSC

Measurement of secreted e $\text{A}\beta_{42}$ (expressed as the ratio e $\text{A}\beta_{42}$ /e $\text{A}\beta_{40}$) is critical for early detection and the disease-modifying treatments necessary to combat AD. Therefore, to assess the amounts of e $\text{A}\beta_{42}$ and e $\text{A}\beta_{40}$ secreted by both WT and mutant ChLNs derived from NPC, MenSCs, and WJ-MSCs, supernatants from culture medium were evaluated by a solid-phase sandwich ELISA according to the standard procedure described in the Section 4. The amount of secreted e $\text{A}\beta_{40}$ was almost constant in both WT and mutant PSEN 1 E280A ChLNs derived from NPC (Figure 10A), MenSCs (Figure 10B), and WJ-MSC (Figure 10C) ChLNs. However, secreted e $\text{A}\beta_{42}$ was significantly higher in the mutant ChLNs when compared to WT ChLNs from all three sources (Figure 10D–F). Interestingly, PSEN 1 E280A ChLNs derived from WJ-MSCs secreted greater amounts of e $\text{A}\beta_{42}$ (Figure 10F, 133 \pm 17 pg/mL) than mutant NPC (Figure 10D, 53 \pm 5 pg/mL), or

mutant MenSCs (Figure 10E, 31 ± 1 pg/mL). As a result, the ratio A β 42/40 was consistently higher in PSEN 1 E280A ChLNs derived from WJ-MSCs (Figure 10I, A β 42/40 = 6) than the other two cellular sources (Figure 10G, A β 42/40 = 1.6; and Figure 10H, A β 42/40 = 1.3). In other words, PSEN 1 E280A WJ-MSCs-derived ChLNs secreted 3.75- and 4.62-folds of A β 42 compared to mutant ChLNs derived from NPC and MenSCs, respectively.

2.8. PSEN 1 E280A Cerebral Spheroids (CSs) Derived from MenSCs, and WJ-MSCs Display Typical iAPP β f, p-Tau and Oxidative Stress (oxDJ-1) Markers as Mutant NPC-Derived CSs

Next, we wondered whether the accumulation of iAPP β fragments, p-Tau, and oxidation of DJ-1 detected in 2D also occurred in 3D (CSs) structures. Figure 11 shows that no OS, iAPP β f or p-Tau markers were present in WT CSs from NPC (Figure 11A,A',A'',B,C,G-I,M-O). In contrast, PSEN 1 E280A NPC-, MenSC-, and WJ-MSCs-derived CSs displayed the typical iAPP β f (Figure 11D,D',E,F), OS (Figure 11D,D',E,F), and p-Tau (Figure 11J,J',K,L) markers, albeit with different levels of intensity (Figure 11M-O). While mutant WJ-MSCs-derived CSs generated higher levels of iAPP β f i.e., in terms of MFI signal, compared to mutant NPC-derived CSs (Figure 11M), mutant NPC-derived CSs showed significantly higher levels of oxidized DJ-1 protein (Figure 11N) compared to either mutant MenSCs-, or mutant WJ-MSCs-derived CSs. Yet, mutant WJ-MSC-derived CSs showed higher levels of p-Tau compared to mutant NPC-derived CSs (Figure 11O).

2.9. PSEN 1 E280A CSs Derived from MenSCs and WJ-MSCs Show Markers of Apoptosis as Mutant NPC-Derived CSs

Based on the above observations, we wanted to confirm that CSs express apoptotic markers. To this aim, phosphorylated JUN, PUMA, TP53, and CASP3 were assessed in both WT and PSEN 1 E280A CSs. As expected, WT NPC-, MenSC-, and WJ-MSCs-derived CSs show neither PUMA (Figure 12A,A',B,C), nor p-JUN (Figure 12A,A',B,C), nor TP53 (Figure 12G,G',H,I), nor CASP3 (Figure 12G,G',H,I) markers (Figure 12M-P). The markers were visible in mutant CSs. Effectively, PSEN 1 E280A NPC-, MenSC-, and WJ-MSCs-derived CSs displayed a statistically significant increase in PUMA (Figure 12D,D',E,F), p-JUN (Figure 12D,D',E,F), TP53 (Figure 12G,J',K,L), and CASP3 (Figure 12J,J',K,L) markers, albeit without following a logical order of expression or activation (Figure 12M-P). While p-JUN was significantly increased in mutant CSs derived from NPC (Figure 12M), activated PUMA was significantly higher in mutant MenSCs (Figure 12N). The apoptotic marker TP53 was significantly increased in both mutant CSs derived from MenSCs and WJ-MSCs (Figure 12O). Like TP53, the executor protein CASP3 was significantly active in both mutant CSs derived from MenSCs and WJ-MSCs (Figure 12P).




Figure 10. ELISA quantification of extracellular Aβ40 and Aβ42 peptides in supernatants from PSEN1 WT and PSEN1 E280A cells. WT and PSEN1 E280A ChLNs cells were left in neural medium or minimal culture medium for 4 days. The levels of secreted Aβ1–40 and Aβ1–42 peptides were determined as described in the Section 4. The ELISA measurements of Aβ40 in the supernatant from WT and PSEN1 E280A cholinergic cells derived from iPSCs (A), MenSCs (B), and WJ-MSCs (C) cells at day 4. The ELISA measurements of Aβ42 in supernatant from WT and PSEN1E280A cholinergic cells derived from iPSCs (D), MenSCs (E), and WJ-MSCs (F) cells at day 4. The Aβ42 over Aβ40 ratio in PSEN1 E280A from iPSCs (G), MenSCs (H), and WJ-MSCs (I) compared with WT at day 4. The figures represent one out of three independent experiments. Significant values were determined by a one-way ANOVA with Tukey’s post hoc test. The data are presented as mean ± SD (* $p < 0.05$; ** $p < 0.01$).




Figure 11. Determination of Alzheimer’s pathological proteins by immunofluorescence in cerebral spheroids (CS). Representative immunofluorescence microscopy of WT (A–C,G–I) and PSEN 1 E280A iPSCs::NPC- (D,J), MenSCs- (E,K), and JW-MSCs-derived ChLNs (F,L) stained to identify iAPPβf (A’,D’,B,C,E,F), ox-DJ-1 (A’’,D’’,B,C,E,F), p-TAU (G’,J’,H–K), t-Tau (G’’,J’’,H–K), and nuclei (A’’’,D’’’,B,C,E,F,H–L). Quantitative data showing the mean fluorescence intensity for iAPPβf (M), ox-DJ-1 (N), and the p-TAU/t-TAU ratio (O). The figures represent one out of three independent experiments. The data are expressed as the mean ± SD; significant values were determined by one-way ANOVA with Tukey’s post hoc test; * $p < 0.05$; ** $p < 0.005$; *** $p < 0.001$. Image magnification, 20×.




Figure 12. Determination of apoptosis-associated proteins by immunofluorescence in cerebral spheroids (CSs). Representative immunofluorescence microscopy of WT (A–C,G–I) and PSEN1 E280A iPSCs::NPC- (D,J), MenSCs- (E,K), and JW-MSCs-derived ChLNs (F,L) stained to identify PUMA (A',D',B,C,E,F), p-c-JUN (A'',D'',B,C,E,F), TP53 (G',J',H–K), CASP3 (G'',J'',H–K), and nuclei (A''',D''',B,C,E,F,H–L). Quantitative data showing the mean fluorescence intensity for PUMA (M), c-p-JUN (N), TP53 (O), and CASP3 (P). The figures represent one out of three independent experiments. The data are expressed as the mean ± SD; significant values were determined by one-way ANOVA with Tukey's post hoc test; * $p < 0.05$; *** $p < 0.001$. Image magnification, 20×.

3. Discussion

Given their resemblance to embryonic stem cells (ESCs), human iPSCs [31] have been instrumental for AD modeling in vitro [32] to understand the underlying mechanisms of the disease (e.g., [33]), test potential drugs [34], and develop personalized therapies [35]. Here, we obtained iPSCs from a WT PSEN 1 subject and from a patient with FAD bearing the mutation PSEN 1 E280A and used both as reference 2D and 3D tissue cultures for revealing the natural neuropathology of FAD and for comparative purposes. Like iPSCs, we established that multipotent MenSCs and WJ-MSCs: (i) expressed the pluripotent-associated markers OCT4, SOX2, NANOG, and KLF4; (ii) differentiated into cells of ectoderm and mesoderm germ layers; (iii) highly expressed neuronal stem marker nestin, and neural stem and progenitor cell marker SOX2; (iv) transdifferentiated into ChLNs, which expressed the cholinergic marker ChAT/VACHT (56 ± 6 & $79 \pm 4\%$); and (vi) transdifferentiated into CSs. Taken together, these observations suggest that MenSCs and WJ-MSCs might be developmentally equivalent to iPSCs. Interestingly, the protocol to obtain ChLNs and CSs from MenSCs and WJ-MSCs lasts 11 days, whereas the protocol for obtaining neurons from iPSCs takes no less than 35 days. Therefore, using both *Cholinergic-N-Run* [29] and *Fast-N-Spheres V2* [30] medium protocols, at least 24 days are free from laboratory work (i.e., a 68% reduction in labor time). It was concluded that under the present conditions, both culture media are highly efficient as inducers of ChLNs. Since cholinergic neurons that form the nucleus basalis of Meynert are the most vulnerable to AD pathology [36], and therefore more severely lost, we considered that most of the 2D and 3D ChLNs in culture are reasonably homologous to ChNs in vivo.

In the present work, we report for the first time that iPSC::NPC-derived (planar or 2D culture) PSEN 1 E280A ChLNs and (3D culture) CSs displayed the neuropathological markers of AD, such as iAPP β f, and the secretion of high amounts of eA β and p-TAU. Similar observations were recorded in 2D and 3D PSEN 1 E280A ChLNs derived from MenSCs (this work) and WJ-MSCs [29,30]. These observations suggest that the abnormal intracellular accumulation of A β seen in PSEN 1 E280A ChLNs and CSs is the earliest pathological event of a continuous process from an initial accumulation of iAPP β f to TAU phosphorylation [37] to the well-established extracellular A β aggregation, culminating in the formation of amyloid plaques [38] and cholinergic cell death. It was concluded that iAPP β f plays an important role in the genesis of PSEN 1 FAD [5]. Although several drugs that remove eA β have failed to demonstrate clinical efficacy, including PSEN 1 E280A-derived A β [39], our in vitro data suggest that other alternative therapies against iA β [40] or Tau protein [41] might be tested. Interestingly, we found oxidation of sensor protein DJ-1 (Cys¹⁰⁶-SO₃) concomitantly with iAPP β f accumulation in PSEN1 E280A iPSCs::NPC-derived ChLNs and CSs. Like mutant iPSCs::NPC-derived neurons, mutant ChLNs derived from MenSCs and WJ-MSCs also consistently showed DJ-1 (Cys¹⁰⁶-SO₃) together with iAPP β f. However, how exactly these two phenomena relate to each other is not yet established. One possible explanation is that iAPP β f directly or indirectly causes mitochondrial electron transport disruption [42,43], thereby bursting into ROS production (e.g., H₂O₂), which in turn might specifically oxidize DJ-1 [44]. In accordance with this assumption, we found that mutant ChLNs and CSs generated ROS (H₂O₂), and induced loss of $\Delta\Psi_m$ concomitantly with Cys¹⁰⁶-SO₃. Whatever the connection might be, we consistently found that neurons expressed amyloidogenic A β , mitochondrial damage, ROS generation, and OS in planar ChLNs and (3D) CSs derived from the three biological sources (iPSCs::NPC, MenSCs, WJ-MSCs). Given that DJ-1 is not only an important stress sensor protein, but also modulates several signaling cellular pathways [45], it becomes a potential biomarker and therapeutic target in AD [46,47].

Interestingly, PSEN 1 E280A ChLNs derived from iPSCs::NPC, MenSCs, and WJ-MSCs reliably showed up-regulation of JUN, TP53, PUMA, and activation of CASP3, all involved in intrinsic apoptosis [48]. Accordingly, the iAPP β f generated H₂O₂ either oxidizes DJ-1 or can function as a second messenger [49], thereby activating other redox signaling proteins (e.g., apoptosis signal-regulating kinase 1 [50,51]), in turn activating the c-Jun N-terminal

Kinase (JNK) pathway [52]. Remarkably, JNK can activate the transcription factor JUN [52], the transcription factor TP53 [53], and phosphorylate the protein Tau [54]. Therefore, JNK might also be a potential therapeutic target for AD [55]. Remarkably, both JUN [56] and TP53 [57,58] transactivate BH3-only protein PUMA, which in turn directly or indirectly induces loss of $\Delta\Psi_m$ through the Bcl-2 pro-apoptotic protein Bax [59]. This last event on mitochondria leads to the release of apoptogenic proteins [60] and the activation of the cellular end executor protein CASP3, which is responsible for neuronal dismantling. Taken together, these results comply with the notion that iAPP β f induces a cascade of events involving OS-signaling, mitochondrial depolarization, p-Tau, and apoptosis [29,61,62] in ChLNs derived from the three biological sources examined. Interestingly, it has been shown that PSEN1 E280A ChLNs derived from WJ-MSCs did not respond to ACh-induced Ca^{2+} influx, most probably due to eA β 42 interaction with nicotinic acetylcholine receptors [63]. We report for the first time that iPSCs::NPC- and MenSCs-derived PSEN1 E280A ChLNs were resilient to ACh-induced Ca^{2+} influx. Together, these results suggest that eA β 42 affects neuronal Ca^{2+} flux in PSEN1 E280A independently of the cellular source tested.

Despite the use of iPSCs, these cells present several disadvantages. For instance, reprogramming highly depends on the efficient delivery and the suitable expression of Yamanaka factors, i.e., OSKM, into specific cell types (e.g., fibroblasts, cord blood CD133+ cells, peripheral blood mononuclear cells). Furthermore, the protocol(s) for obtaining reprogrammed cells is rather a slow and vulnerable process that may be affected by several factors (e.g., biopsy, cell type, particular culture conditions, long culture period) that hinder the efficiency, reproducibility, and quality of the resulting iPSCs (e.g., [64–66]). Therefore, replacement of iPSCs with a more manageable, cost-effective, time-saving biologic source that offers similarities to iPSCs is highly desirable.

In conclusion, we have demonstrated that PSEN1 E280A ChLNs and cholinergic CSs derived from MenSCs, WJ-MSCs, and iPSCs can reliably reproduce the neuropathology of FAD *in vitro*, and therefore, they are cellularly and biochemically equivalent. Accordingly, PSEN1 E280A iPSCs can be interchangeable with PSEN1 E280A MenSCs and PSEN1 E280A WJ-MSCs. Furthermore, they expressed the typical cellular hallmarks of AD, i.e., eA β 42 and p-TAU. Additionally, the presence of iA β , oxidative markers DJ-1 Cys¹⁰⁶-SO₃ and p-JUN, loss of $\Delta\Psi_m$, apoptosis markers TP53, PUMA, and CASP3, and dysfunctional ACh-induced Ca^{2+} influx were observed in mutant ChLNs and CSs in 11 days, whereas at least 35 days of culture are necessary to reproduce AD markers from mutant iPSCs::NPCs. This labor time-gap in favor of MenSCs and WJ-MSCs makes these biological sources much more attractive not only for modeling FAD but also for speeding up drug discoveries (e.g., antioxidant compounds [67]). However, to fully validate our findings, dissecting transcriptomic signatures of cholinergic neuronal differentiation using PSEN1 E280A iPSCs (as reference tissue [68]), MenSCs and WJ-MSCs is warranted. Whatever the cause, cholinergic degeneration remains one of the earliest, most severe, and most consistent cellular changes in AD. Therefore, studying the cellular and molecular changes in cholinergic neurons may provide clues to the pathogenesis and treatment of this disorder [69]. Moreover, MSC-based therapy might be a promising alternative for the treatment of AD [70,71].

4. Materials and Methods

4.1. Human Menstrual Stromal Cells (MenSCs) and Wharton Jelly-Mesenchymal Stromal Cells (WJ-MSCs)

The menstrual blood (MenB) samples were collected from one healthy female and one female carrier of the mutation PSEN1 E280A aged 30 years (Tissue Bank Code, TBC#69308) and 25 years (TBC#04335) according to ref. [28]. The WT (TBC# WJ-MSC-15) and PSEN1 E280A (TBC# WJ-MSC-12) were collected as described previously [29]. Donors signed an informed consent accepted by the Ethics Committee of the Sede de Investigación Universitaria-SIU-, Act#2020-10854, University of Antioquia, Medellín, Colombia.

4.2. Cholinergic-like Neuron (ChLN) Differentiation

ChLN differentiation was performed according to ref. [28]. Briefly, WT and mutant MenSCs and WJ-MSCs were seeded at $1\text{--}1.5 \times 10^4$ cells/cm² in laminin-treated culture plates for 24 h in regular culture medium. Then, the medium was removed, and cells were incubated in cholinergic differentiation medium (*Cholinergic-N-Run* medium, hereafter *Ch-N-Rm*) at 37 °C for 7 days, and then the medium was replaced by minimal culture medium (mCM) for 4 days.

4.3. Human Induced Pluripotent Stem Cell (iPSC) Lines Culture and Differentiation

Reprogramming of human primary skin fibroblasts from 2 adult donors (PSEN1 WT: Ctrl-4 and E280A: p106) was performed using a single, multicistronic lentiviral vector encoding OCT4, SOX2, KLF4, and MYC according to ref. [31] in Dr. Kosik's laboratory. Donors provided written informed consent in accordance with the Medical Ethical Committee of the University of Antioquia. The iPSC cells were thawed and cultivated on VTN-N (Cat# A14700, Thermo Fisher Scientific Inc., Santa Fe, NM, USA)-coated 6-well plates to form colonies in Drs. Velez-Jimenez's laboratory. Human iPSC cells were mechanically detached from the VTN-N surface. Embryoid bodies (EBs) were generated by transferring iPSCs to non-adherent plates in E6 medium at 37 °C in 5% CO₂. After 7 days, EBs were transferred to a non-adherent plate, and E6 medium (Cat# A1516401, GIBCO, Santa Fe, NM, USA) was supplemented with 10 ng/mL bFGF (Cat# F0291-25UG, Sigma-Aldrich, St. Louis, MO, USA). After 2 days, the floating structures were dissociated by trituration and transferred to a VTN-N-treated dish. For generation of neural progenitor cells (NPCs), EBs were cultured in NPC medium (Neurobasal medium, Cat# 21103049, GIBCO, Santa Fe, NM, USA; 1% N2 supplement, Cat# 17502048, GIBCO, Santa Fe, NM, USA; 2% B27 supplement, Cat# 17504044, GIBCO, Santa Fe, NM, USA), 20 ng/mL epidermal growth factor (Cat# E5036, Sigma-Aldrich, St. Louis, MO, USA), 1 µg/mL heparin sodium salt (Cat# 375095, Sigma-Aldrich, St. Louis, MO, USA), 1 ng/mL bFGF (Cat# F0291-25UG, Sigma-Aldrich, St. Louis, MO, USA), 1 × β-mercaptoethanol (Cat# M3148-100ML, Sigma-Aldrich, St. Louis, MO, USA) and 1% penicillin/streptomycin (Cat# 15140122, GIBCO, Santa Fe, NM, USA) for 18 days. NPC were seeded at 3×10^4 cells/cm² in 24-well culture flasks for 24 h in NPC culture medium. Then, the medium was removed, and cells were incubated in cholinergic differentiation medium (*Cholinergic-N-Run*) at 37 °C for 2 days [19]. After cholinergic induction, the medium was replaced and refreshed with neural medium (NM), composed by neurobasal medium supplemented with 1 × N2 and 1% penicillin/streptomycin.

4.4. Generation of Cerebral Spheroids (CSs)

Cerebral spheroids were obtained by differentiation of WT or PSEN1 E280A from iPSC-derived NPC, MenSCs, and WJ-MSCs, as previously described in ref. [30]. Briefly, WT and mutant NPC, MenSCs, or WJ-MSCs were cultured in a brand-new medium called *Fast-N-Spheres V2* plus Corning Matrigel® (Cat# 356232, Thermo Fisher Scientific Inc., Santa Fe, NM, USA) and 1% fetal bovine serum (FBS; Cat# CVFVSF00-01, Eurobio Scientific, Les Ulis, France). Cultures were constantly shaken for 2 days. Then, CSs medium was replaced by neuronal medium (NM) and left under incubation for 6 or 11 days, depending on tissue resources.

Evaluation of pluripotent-, and neuronal-associated markers Initially, iPSCs, MenSCs, and WJ-MSCs were characterized for the pluripotent-associated markers OCT4 (Cat# A13998, Invitrogen, Waltham, MA, USA), SOX2 (Cat# PA1-094, Thermo Fisher Scientific Inc., Santa Fe, NM, USA), NANOG (Cat# AB9220, Millipore, Burlington, MA, USA) and KLF4 (Cat# MA5-15695, Invitrogen, Waltham, MA, USA). Then, iPSCs were differentiated into NPC and subsequently differentiated into cholinergic cells, or CSs. Similarly, MenSCs and WJ-MSCs were transdifferentiated into ChLNs or cerebral spheroids. Finally, cells, or CSs, were used to evaluate neuronal markers and AD-associated pathological proteins.

4.5. Immunofluorescence Analysis

The immunofluorescence analysis of the different neuropathological markers related to FAD was performed according to ref. [29]. Briefly, the neuronal cells, or CSs incubated under different conditions were fixed with cold ethanol ($-20\text{ }^{\circ}\text{C}$; Cat# 459836-500ML, Sigma-Aldrich, St. Louis, MO, USA) for 20 min. Then, cells were washed three times over 5 min with PBS, followed by Triton X-100 (0.1%; Cat# 93443, Sigma-Aldrich, St. Louis, MO, USA) permeabilization and 10% bovine serum albumin (BSA; Cat# A9418, Sigma-Aldrich, St. Louis, MO, USA) blockage for 30 min at room temperature. Cells were incubated overnight with primary antibodies against the pluripotency transcription factors OCT4 (1:500), SOX-2 (1:500), NANOG (1:500), and KLF4 (1:500) and the neuronal marker Nestin (1:500; cat# MA1-5840, Invitrogen, Waltham, MA, USA). Neuronal precursor markers such as β -3 tubulin, GFAP, ChAT, the pathological/apoptosis associated proteins APP751 and/or protein amyloid β 1-42, total TAU, phospho-TAU, PUMA, p53, caspase-3, and oxidative stress markers DJ-1 and phospho-c-Jun were used according to ref. [29]. Finally, cells were washed (three times over 5 min with PBS) and incubated with secondary fluorescent antibodies DyLight 488 and 594 (cat# DI 1094, cat# DI 3088, and cat# DI 2488, Vector Laboratories, Newark, NJ, USA), according to ref. [29].

4.6. Evaluation of Intracellular Hydrogen Peroxide (H_2O_2) by Fluorescence Microscopy

The levels of intracellular H_2O_2 , were determined according to ref. [29]. Briefly, cells were left in neural medium (NM) for 0 and 4 days or in minimal culture media (mCM) for 4 days. Then, the cells (5×10^3) were incubated with 2',7'-dichlorofluorescein diacetate reagent ($5\text{ }\mu\text{M}$, DCFH₂-DA; Cat# D399, Invitrogen, Waltham, MA, USA) for 30 min at $37\text{ }^{\circ}\text{C}$ in the dark. Cells were then washed, and DCF fluorescence intensity was determined by analysis of fluorescence microscopy images. The assessment was repeated three times in independent experiments, blind to the experimenter.

4.7. Analysis of Mitochondrial Membrane Potential ($\Delta\Psi_m$) by Fluorescence Microscopy

The ChLNs were left in NM for 0–4 days or in mCM for 4 days. Then, the cells (5×10^3) were incubated with the passively diffusing and active mitochondria-accumulating dye deep red MitoTracker compound (20 nM , final concentration) for 20 min at RT in the dark (cat# M22426, Invitrogen, Waltham, MA, USA) according to ref. [29]. The assessment was repeated three times in independent experiments.

4.8. Intracellular Calcium Imaging

Intracellular calcium (Ca^{2+}) concentration changes evoked by cholinergic stimulation were assessed according to refs. [72,73] with minor modifications. Briefly, for the measurement, the fluorescent dye Fluo-3 (Fluo-3 AM; cat: F1242 Thermo Fisher Scientific, Santa Fe, NM, USA) was employed. Intracellular Ca^{2+} transients were evoked by acetylcholine (ACh; Cat# A2661, Sigma-Aldrich, St. Louis, MO, USA); 1 mM final concentration) at 4 days post differentiation. The amplitudes of the Ca^{2+} -related fluorescence transients were expressed relative to the resting fluorescence ($\Delta F/F$) and were calculated by the following formula: $\Delta F/F = (F_{\text{maximum}} - F_{\text{resting}})/(F_{\text{resting}} - F_{\text{background}})$. For the calculation of the fluorescence intensities, ImageJ was used. The assessment was repeated three times in independent experiments, blind to the experimenter.

4.9. Measurement of $\text{A}\beta$ 1–40 and $\text{A}\beta$ 1–42 Peptides in Culture Medium

The levels of $\text{A}\beta$ 1–40 and $\text{A}\beta$ 1–42 peptides were measured according to a previous report with minor modifications. Briefly, WT and PSEN1 E280A cells were left in NM or mCM for 4 days. Then, $100\text{ }\mu\text{L}$ of supernatants were collected, and the levels of secreted $\text{A}\beta$ 1–40 and $\text{A}\beta$ 1–42 peptides were determined by a solid-phase sandwich ELISA (Cat# 150496 and Cat# 574166, respectively, Abbexa, Cambridge, UK) following the manufacturer's instructions. The assessment was repeated three times in independent experiments, blind to the experimenter.

4.10. Photomicrography and Image Analysis

Light microscopy photographs were taken using a Zeiss Axiovert 50 Fluorescence Microscope (Carl Zeiss, Gottingen, Germany) equipped with a Canon PowerShot G5 digital camera (Zeiss Wöhlk-Contact-Linsen, Gmb Schöckirchen, Gottingen, Germany), and fluorescence microscopy photographs were taken using a Zeiss Axiovert A1 Fluorescence Microscope equipped with a Zeiss AxioCam Cm1 and (Zeiss Wöhlk-Contact-Linsenfluoreen, Gmb Schöckirchen, Gottingen, Germany) and Fluid Cells Imaging Station microscope (Cat# 4471136, Life Technologies, Carlsbad, CA, USA). Fluorescence images were analyzed by ImageJ software (<http://imagej.nih.gov/ij/>, accessed on 7 May 2023). Mean fluorescence intensity (MFI) was obtained by normalizing total fluorescence to the number of nuclei.

4.11. Data Analysis

In this experimental design, two vials of each specimen/origin were thawed (PSEN1-WT and -E280A), cultured, and the cell suspension was pipetted at a standardized cellular density of 2.6×10^4 cells/cm² into different wells of a 24-well plate. Experiments were conducted in triplicate wells, according to ref. [29]. The data from individual replicate wells were averaged to yield a value of $n = 1$ for that experiment, and this was repeated on three occasions, blind to the experimenter and/or flow cytometer analyst, for a final value of $n = 3$ [74]. The data were analyzed according to ref. [29]. The statistical significance was determined by one-way analysis of variance (ANOVA) followed by Tukey's post hoc comparison calculated with GraphPad Prism 5.0 software (<https://www.graphpad.com/>; accessed on 5 February 2023). Differences between groups were only deemed significant when a p -value of <0.05 (*), <0.001 (**) and <0.001 (***). All data are illustrated as the mean \pm S.D.

Author Contributions: Conceptualization, M.J.-D.-R., C.V.-P.; Methodology, M.M.-P., C.V.-P., M.J.-D.-R.; Validation, M.M.-P.; Formal analysis, M.M.-P., C.V.-P., M.J.-D.-R.; Investigation, M.M.-P., M.J.-D.-R., C.V.-P.; Resources, K.S.K., F.L., M.J.-D.-R.; Data Curation, M.M.-P.; Project administration, M.J.-D.-R., K.S.K., F.L.; Visualization, M.M.-P., C.V.-P.; Supervision, M.J.-D.-R., K.S.K., F.L.; Writing—original draft, C.V.-P., M.J.-D.-R.; Writing—review & editing, M.M.-P., C.V.-P., K.S.K., F.L., M.J.-D.-R. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by National Institute on Aging, grant number 1RF1AG062479-01 and The APC was funded by NIA.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the Hospital San Vicente Fundacion Research act#13–2015, and Sede de Investigación Universitaria (SIU), University of Antioquia, Medellín, Colombia, act#20-10-854-2020.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: All relevant data are within the manuscript.

Acknowledgments: We greatly acknowledge J Acosta-Urbe for iPSCs management.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Mesulam, M.M. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease. *J. Comp. Neurol.* **2013**, *521*, 4124–4144. [[CrossRef](#)] [[PubMed](#)]
2. Lin, C.P.; Frigerio, I.; Boon, B.D.C.; Zhou, Z.; Rozemuller, A.J.M.; Bouwman, F.H.; Schoonheim, M.M.; van de Berg, W.D.J.; Jonkman, L.E. Structural (dys)connectivity associates with cholinergic cell density in Alzheimer's disease. *Brain* **2022**, *145*, 2869–2881. [[CrossRef](#)] [[PubMed](#)]
3. DeTure, M.A.; Dickson, D.W. The neuropathological diagnosis of Alzheimer's disease. *Mol. Neurodegener.* **2019**, *14*, 32. [[CrossRef](#)]
4. Knopman, D.S.; Amieva, H.; Petersen, R.C.; Chételat, G.; Holtzman, D.M.; Hyman, B.T.; Nixon, R.A.; Jones, D.T. Alzheimer disease. *Nat. Rev. Dis. Primers* **2021**, *7*, 33. [[CrossRef](#)] [[PubMed](#)]
5. Gallego Villarejo, L.; Bachmann, L.; Marks, D.; Brachthäuser, M.; Geidies, A.; Müller, T. Role of Intracellular Amyloid β as Pathway Modulator, Biomarker, and Therapy Target. *Int. J. Mol. Sci.* **2022**, *23*, 4656. [[CrossRef](#)]

6. Hampel, H.; Vergallo, A.; Aguilar, L.F.; Benda, N.; Broich, K.; Cuello, A.C.; Cummings, J.; Dubois, B.; Federoff, H.J.; Fiandaca, M.; et al. Precision pharmacology for Alzheimer's disease. *Pharmacol. Res.* **2018**, *130*, 331–365. [[CrossRef](#)] [[PubMed](#)]
7. Funamoto, S.; Tagami, S.; Okochi, M.; Morishima-Kawashima, M. Successive cleavage of β -amyloid precursor protein by γ -secretase. *Semin. Cell Dev. Biol.* **2020**, *105*, 64–74. [[CrossRef](#)]
8. Suzuki, T.; Sobu, Y.; Hata, S. γ -Secretase structure and activity are modified by alterations in its membrane localization and ambient environment. *J. Biochem.* **2022**, *171*, 253–256. [[CrossRef](#)]
9. Kim, M.; Bezprozvanny, I. Conformational Models of APP Processing by Gamma Secretase Based on Analysis of Pathogenic Mutations. *Int. J. Mol. Sci.* **2021**, *22*, 3600. [[CrossRef](#)]
10. Lalli, M.A.; Cox, H.C.; Arcila, M.L.; Cadavid, L.; Moreno, S.; Garcia, G.; Madrigal, L.; Reiman, E.M.; Arcos-Burgos, M.; Bedoya, G.; et al. Origin of the PSEN1 E280A mutation causing early-onset Alzheimer's disease. *Alzheimer's Dement.* **2014**, *10*, S277–S283.e10. [[CrossRef](#)]
11. Tariot, P.N.; Lopera, F.; Langbaum, J.B.; Thomas, R.G.; Hendrix, S.; Schneider, L.S.; Rios-Romenets, S.; Giraldo, M.; Acosta, N.; Tobon, C.; et al. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. *Alzheimer's Dement.* **2018**, *4*, 150–160. [[CrossRef](#)]
12. Reiman, E.M.; Pruzin, J.J.; Rios-Romenets, S.; Brown, C.; Giraldo, M.; Acosta-Baena, N.; Tobon, C.; Hu, N.; Chen, Y.; Ghisays, V.; et al. A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial. *Alzheimer's Dement.* **2023**, *19*, 1938–1946. [[CrossRef](#)] [[PubMed](#)]
13. Young, J.E.; Goldstein, L.S.B. Human-Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons and Glia for the Elucidation of Pathogenic Mechanisms in Alzheimer's Disease. *Methods Mol. Biol.* **2023**, *2561*, 105–133. [[CrossRef](#)]
14. Yagi, T.; Ito, D.; Okada, Y.; Akamatsu, W.; Nihei, Y.; Yoshizaki, T.; Yamanaka, S.; Okano, H.; Suzuki, N. Modeling familial Alzheimer's disease with induced pluripotent stem cells. *Hum. Mol. Genet.* **2011**, *20*, 4530–4539. [[CrossRef](#)] [[PubMed](#)]
15. Yang, J.; Zhao, H.; Ma, Y.; Shi, G.; Song, J.; Tang, Y.; Li, S.; Li, T.; Liu, N.; Tang, F.; et al. Early pathogenic event of Alzheimer's disease documented in iPSCs from patients with PSEN1 mutations. *Oncotarget* **2017**, *8*, 7900–7913. [[CrossRef](#)]
16. Li, L.; Roh, J.H.; Chang, E.H.; Lee, Y.; Lee, S.; Kim, M.; Koh, W.; Chang, J.W.; Kim, H.J.; Nakanishi, M.; et al. iPSC Modeling of Presenilin1 Mutation in Alzheimer's Disease with Cerebellar Ataxia. *Exp. Neurobiol.* **2018**, *27*, 350–364. [[CrossRef](#)]
17. Vallejo-Diez, S.; Fleischer, A.; Martín-Fernández, J.M.; Sánchez-Gilabert, A.; Castresana, M.; Aguillón, D.; Villegas, A.; Mastronardi, C.A.; Espinosa, L.G.; Arcos-Burgos, M.; et al. Generation of one iPSC line (IMEDEAI006-A) from an early-onset familial Alzheimer's Disease (fAD) patient carrying the E280A mutation in the PSEN1 gene. *Stem Cell Res.* **2019**, *37*, 101440. [[CrossRef](#)]
18. Frederiksen, H.R.; Holst, B.; Mau-Holzmann, U.A.; Freude, K.; Schmid, B. Generation of two isogenic iPSC lines with either a heterozygous or a homozygous E280A mutation in the PSEN1 gene. *Stem Cell Res.* **2019**, *35*, 101403. [[CrossRef](#)]
19. Mendivil-Perez, M.; Velez-Pardo, C.; Kosik, K.S.; Lopera, F.; Jimenez-Del-Rio, M. iPSCs-derived nerve-like cells from familial Alzheimer's disease PSEN 1 E280A reveal increased amyloid-beta levels and loss of the Y chromosome. *Neurosci. Lett.* **2019**, *703*, 111–118. [[CrossRef](#)]
20. Hu, Y.; Qu, Z.Y.; Cao, S.Y.; Li, Q.; Ma, L.; Krencik, R.; Xu, M.; Liu, Y. Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells. *J. Neurosci. Methods* **2016**, *266*, 42–49. [[CrossRef](#)]
21. Lv, H.; Hu, Y.; Cui, Z.; Jia, H. Human menstrual blood: A renewable and sustainable source of stem cells for regenerative medicine. *Stem Cell Res. Ther.* **2018**, *9*, 325. [[CrossRef](#)] [[PubMed](#)]
22. Marino, L.; Castaldi, M.A.; Rosamilio, R.; Ragni, E.; Vitolo, R.; Fulgione, C.; Castaldi, S.G.; Serio, B.; Bianco, R.; Guida, M.; et al. Mesenchymal Stem Cells from the Wharton's Jelly of the Human Umbilical Cord: Biological Properties and Therapeutic Potential. *Int. J. Stem Cells* **2019**, *12*, 218–226. [[CrossRef](#)] [[PubMed](#)]
23. Borys-Wójcik, S.; Brazert, M.; Jankowski, M.; Ożegowska, K.; Chermuła, B.; Piotrowska-Kempisty, H.; Bukowska, D.; Antosik, P.; Pawelczyk, L.; Nowicki, M.; et al. Human Wharton's jelly mesenchymal stem cells: Properties, isolation and clinical applications. *J. Biol. Regul. Homeost. Agents* **2019**, *33*, 119–123. [[PubMed](#)]
24. Bozorgmehr, M.; Gurung, S.; Darzi, S.; Nikoo, S.; Kazemnejad, S.; Zarnani, A.H.; Gargett, C.E. Endometrial and Menstrual Blood Mesenchymal Stem/Stromal Cells: Biological Properties and Clinical Application. *Front. Cell Dev. Biol.* **2020**, *8*, 497. [[CrossRef](#)] [[PubMed](#)]
25. Zhang, H.T.; Fan, J.; Cai, Y.Q.; Zhao, S.J.; Xue, S.; Lin, J.H.; Jiang, X.D.; Xu, R.X. Human Wharton's jelly cells can be induced to differentiate into growth factor-secreting oligodendrocyte progenitor-like cells. *Differentiation* **2010**, *79*, 15–20. [[CrossRef](#)]
26. Bonilla-Porras, A.R.; Velez-Pardo, C.; Jimenez-Del-Rio, M. Fast transdifferentiation of human Wharton's jelly mesenchymal stem cells into neurospheres and nerve-like cells. *J. Neurosci. Methods* **2017**, *282*, 52–60. [[CrossRef](#)] [[PubMed](#)]
27. Mendivil-Perez, M.; Velez-Pardo, C.; Jimenez-Del-Rio, M. Direct transdifferentiation of human Wharton's jelly mesenchymal stromal cells into cholinergic-like neurons. *J. Neurosci. Methods* **2019**, *312*, 126–138. [[CrossRef](#)]
28. Quintero-Espinosa, D.; Soto-Mercado, V.; Quintero-Quinchia, C.; Mendivil-Perez, M.; Velez-Pardo, C.; Jimenez-Del-Rio, M. Latent Tri-lineage Potential of Human Menstrual Blood-Derived Mesenchymal Stromal Cells Revealed by Specific In Vitro Culture Conditions. *Mol. Neurobiol.* **2021**, *58*, 5194–5209. [[CrossRef](#)]
29. Soto-Mercado, V.; Mendivil-Perez, M.; Velez-Pardo, C.; Lopera, F.; Jimenez-Del-Rio, M. Cholinergic-like neurons carrying PSEN1 E280A mutation from familial Alzheimer's disease reveal intraneuronal sAPP β fragments accumulation, hyperphosphorylation of TAU, oxidative stress, apoptosis and Ca²⁺ dysregulation: Therapeutic implications. *PLoS ONE* **2020**, *15*, e0221669. [[CrossRef](#)]

30. Soto-Mercado, V.; Mendivil-Perez, M.; Velez-Pardo, C.; Jimenez-Del-Rio, M. Neuroprotective Effect of Combined Treatment with Epigallocatechin 3-Gallate and Melatonin on Familial Alzheimer's Disease PSEN1 E280A Cerebral Spheroids Derived from Menstrual Mesenchymal Stromal Cells. *J. Alzheimer's Dis.* **2023**. preprint. [[CrossRef](#)]
31. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* **2007**, *131*, 861–872. [[CrossRef](#)] [[PubMed](#)]
32. Penney, J.; Ralvenius, W.T.; Tsai, L.H. Modeling Alzheimer's disease with iPSC-derived brain cells. *Mol. Psychiatry* **2020**, *25*, 148–167. [[CrossRef](#)] [[PubMed](#)]
33. Takata, M.; Nishimura, K.; Harada, K.; Iwasaki, R.; Ando, M.; Yamada, S.; Ginhoux, F.; Takata, K. Analysis of A β -induced neurotoxicity and microglial responses in simple two- and three-dimensional human iPSC-derived cortical culture systems. *Tissue Cell* **2023**, *81*, 102023. [[CrossRef](#)]
34. Bonaventura, G.; Iemmolo, R.; Attaguile, G.A.; La Cognata, V.; Pistone, B.S.; Raudino, G.; D'Agata, V.; Cantarella, G.; Barcellona, M.L.; Cavallaro, S. iPSCs: A Preclinical Drug Research Tool for Neurological Disorders. *Int. J. Mol. Sci.* **2021**, *22*, 4596. [[CrossRef](#)] [[PubMed](#)]
35. Yefroyev, D.A.; Jin, S. Induced Pluripotent Stem Cells for Treatment of Alzheimer's and Parkinson's Diseases. *Biomedicines* **2022**, *10*, 208. [[CrossRef](#)]
36. Hampel, H.; Mesulam, M.M.; Cuello, A.C.; Farlow, M.R.; Giacobini, E.; Grossberg, G.T.; Khachaturian, A.S.; Vergallo, A.; Cavedo, E.; Snyder, P.J.; et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. *Brain* **2018**, *141*, 1917–1933. [[CrossRef](#)] [[PubMed](#)]
37. Bloom, G.S. Amyloid-beta and tau: The trigger and bullet in Alzheimer disease pathogenesis. *JAMA Neurol.* **2014**, *71*, 505–508. [[CrossRef](#)]
38. Lemere, C.A.; Lopera, F.; Kosik, K.S.; Lendon, C.L.; Ossa, J.; Saido, T.C.; Yamaguchi, H.; Ruiz, A.; Martinez, A.; Madrigal, L.; et al. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. *Nat. Med.* **1996**, *2*, 1146–1150. [[CrossRef](#)]
39. Belluck, P. Trial of New Alzheimer's Drug Reports Disappointing Results. The drug, crenezumab, failed to prevent early symptoms or slow cognitive decline, the latest setback in the long quest to find effective therapies for the disease. *The New York Times*, 16 June 2022.
40. Ohyagi, Y. Intracellular amyloid beta-protein as a therapeutic target for treating Alzheimer's disease. *Curr. Alzheimer Res.* **2008**, *5*, 555–561. [[CrossRef](#)]
41. Aillaud, I.; Funke, S.A. Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease. *Cell Mol. Neurobiol.* **2023**, *43*, 951–961. [[CrossRef](#)]
42. Sinclair, P.; Baranova, A.; Kabbani, N. Mitochondrial Disruption by Amyloid Beta 42 Identified by Proteomics and Pathway Mapping. *Cells* **2021**, *10*, 2380. [[CrossRef](#)] [[PubMed](#)]
43. Gezen-Ak, D.; Yurttaş, Z.; Çamoğlu, T.; Dursun, E. Could Amyloid- β 1-42 or α -Synuclein Interact Directly with Mitochondrial DNA? A Hypothesis. *ACS Chem. Neurosci.* **2022**, *13*, 2803–2812. [[CrossRef](#)] [[PubMed](#)]
44. Kinumi, T.; Kimata, J.; Taira, T.; Ariga, H.; Niki, E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. *Biochem. Biophys. Res. Commun.* **2004**, *317*, 722–728. [[CrossRef](#)]
45. Neves, M.; Grãos, M.; Anjo, S.I.; Manadas, B. Modulation of signaling pathways by DJ-1: An updated overview. *Redox Biol.* **2022**, *51*, 102283. [[CrossRef](#)] [[PubMed](#)]
46. Hijioka, M.; Inden, M.; Yanagisawa, D.; Kitamura, Y. DJ-1/PARK7: A New Therapeutic Target for Neurodegenerative Disorders. *Biol. Pharm. Bull.* **2017**, *40*, 548–552. [[CrossRef](#)] [[PubMed](#)]
47. Huang, M.; Chen, S. DJ-1 in neurodegenerative diseases: Pathogenesis and clinical application. *Prog. Neurobiol.* **2021**, *204*, 102114. [[CrossRef](#)]
48. Galluzzi, L.; Vitale, I.; Aaronson, S.A.; Abrams, J.M.; Adam, D.; Agostinis, P.; Alnemri, E.S.; Altucci, L.; Amelio, I.; Andrews, D.W.; et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death Differ.* **2018**, *25*, 486–541. [[CrossRef](#)]
49. Di Marzo, N.; Chisci, E.; Giovannoni, R. The Role of Hydrogen Peroxide in Redox-Dependent Signaling: Homeostatic and Pathological Responses in Mammalian Cells. *Cells* **2018**, *7*, 156. [[CrossRef](#)]
50. Saitoh, M.; Nishitoh, H.; Fujii, M.; Takeda, K.; Tobiume, K.; Sawada, Y.; Kawabata, M.; Miyazono, K.; Ichijo, H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. *EMBO J.* **1998**, *17*, 2596–2606. [[CrossRef](#)]
51. Goldman, E.H.; Chen, L.; Fu, H. Activation of apoptosis signal-regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 and 14-3-3 dissociation. *J. Biol. Chem.* **2004**, *279*, 10442–10449. [[CrossRef](#)]
52. Morrison, D.K. MAP kinase pathways. *Cold Spring Harb. Perspect. Biol.* **2012**, *4*, a011254. [[CrossRef](#)] [[PubMed](#)]
53. Fuchs, S.Y.; Adler, V.; Pincus, M.R.; Ronai, Z. MEK1/JNK signaling stabilizes and activates p53. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 10541–10546. [[CrossRef](#)]
54. Yoshida, H.; Hastie, C.J.; McLauchlan, H.; Cohen, P.; Goedert, M. Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). *J. Neurochem.* **2004**, *90*, 352–358. [[CrossRef](#)] [[PubMed](#)]
55. Yarza, R.; Vela, S.; Solas, M.; Ramirez, M.J. c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer's Disease. *Front. Pharmacol.* **2015**, *6*, 321. [[CrossRef](#)] [[PubMed](#)]

56. Lu, H.; Hou, G.; Zhang, Y.; Dai, Y.; Zhao, H. c-Jun transactivates Puma gene expression to promote osteoarthritis. *Mol. Med. Rep.* **2014**, *9*, 1606–1612. [[CrossRef](#)]
57. Yu, J.; Zhang, L.; Hwang, P.M.; Kinzler, K.W.; Vogelstein, B. PUMA induces the rapid apoptosis of colorectal cancer cells. *Mol. Cell* **2001**, *7*, 673–682. [[CrossRef](#)]
58. Nakano, K.; Vousden, K.H. PUMA, a novel proapoptotic gene, is induced by p53. *Mol. Cell* **2001**, *7*, 683–694. [[CrossRef](#)]
59. Luo, X.; O'Neill, K.L.; Huang, K. The third model of Bax/Bak activation: A Bcl-2 family feud finally resolved? *F1000Research* **2020**, *9*, 935. [[CrossRef](#)]
60. Dorstyn, L.; Akey, C.W.; Kumar, S. New insights into apoptosome structure and function. *Cell Death Differ.* **2018**, *25*, 1194–1208. [[CrossRef](#)]
61. Stadelmann, C.; Deckwerth, T.L.; Srinivasan, A.; Bancher, C.; Brück, W.; Jellinger, K.; Lassmann, H. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. *Am. J. Pathol.* **1999**, *155*, 1459–1466. [[CrossRef](#)]
62. Tagami, S.; Tsujimoto, Y.; Akaike, A.; Takashima, A.; Hasegawa, M.; Ishiguro, K.; Shoji, M.; Ito, N.; Kanemaru, K.; Urakami, K.; et al. Involvement of apoptosis and cholinergic dysfunction in Alzheimer's disease. *Psychogeriatrics* **2006**, *6*, S57–S63. [[CrossRef](#)]
63. Soto-Mercado, V.; Mendivil-Perez, M.; Jimenez-Del-Rio, M.; Velez-Pardo, C. Multi-Target Effects of the Cannabinoid CP55940 on Familial Alzheimer's Disease PSEN1 E280A Cholinergic-Like Neurons: Role of CB1 Receptor. *J. Alzheimer's Dis.* **2020**, *82*, S359–S378. [[CrossRef](#)]
64. Pistollato, F.; Canovas-Jorda, D.; Zagoura, D.; Price, A. Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing. *J. Vis. Exp.* **2017**, *124*, 55702. [[CrossRef](#)]
65. Vlahos, K.; Sourris, K.; Mayberry, R.; McDonald, P.; Bruveris, F.F.; Schiesser, J.V.; Bozaoglu, K.; Lockhart, P.J.; Stanley, E.G.; Elefanty, A.G. Generation of iPSC lines from peripheral blood mononuclear cells from 5 healthy adults. *Stem Cell Res.* **2019**, *34*, 101380. [[CrossRef](#)]
66. Rivera, T.; Zhao, Y.; Ni, Y.; Wang, J. Human-Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions. *Curr. Protoc. Stem Cell Biol.* **2020**, *54*, e117. [[CrossRef](#)] [[PubMed](#)]
67. Hatami, M.; Mortazavi, M.; Baseri, Z.; Khani, B.; Rahimi, M.; Babaei, S. Antioxidant Compounds in the Treatment of Alzheimer's Disease: Natural, Hybrid, and Synthetic Products. *Evid. Based Complement. Alternat. Med.* **2023**, *2023*, 8056462. [[CrossRef](#)] [[PubMed](#)]
68. Burke, E.E.; Chenoweth, J.G.; Shin, J.H.; Collado-Torres, L.; Kim, S.K.; Micali, N.; Wang, Y.; Colantuoni, C.; Straub, R.E.; Hoepfner, D.J.; et al. Dissecting transcriptomic signatures of neuronal differentiation and maturation using iPSCs. *Nat. Commun.* **2020**, *11*, 462. [[CrossRef](#)]
69. Chen, L.; Qu, J.; Cheng, T.; Chen, X.; Xiang, C. Menstrual blood-derived stem cells: Toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases. *Stem Cell Res. Ther.* **2019**, *10*, 406. [[CrossRef](#)]
70. Thanaskody, K.; Jusop, A.S.; Tye, G.J.; Wan Kamarul Zaman, W.S.; Dass, S.A.; Nordin, F. MSCs vs. iPSCs: Potential in therapeutic applications. *Front. Cell Dev. Biol.* **2022**, *10*, 1005926. [[CrossRef](#)]
71. Gonçalves, R.G.J.; Vasques, J.F.; da Silva-Junior, A.J.; Gubert, F.; Mendez-Otero, R. Mesenchymal stem cell- and extracellular vesicle-based therapies for Alzheimer's disease: Progress, advantages, and challenges. *Neural. Regen. Res.* **2023**, *18*, 1645–1651. [[CrossRef](#)]
72. Pap, P.; Koszeghy, A.; Szucs, G.; Rusznak, Z. Cytoplasmic Ca²⁺ concentration changes evoked by cholinergic stimulation in primary astrocyte cultures prepared from the rat cochlear nucleus. *Hear Res.* **2009**, *255*, 73–83. [[CrossRef](#)] [[PubMed](#)]
73. Sekiguchi-Tonosaki, M.; Obata, M.; Haruki, A.; Himi, T.; Kosaka, J. Acetylcholine induces Ca²⁺ signaling in chicken retinal pigmented epithelial cells during dedifferentiation. *Am. J. Physiol. Cell Physiol.* **2009**, *296*, C1195–C1206. [[CrossRef](#)] [[PubMed](#)]
74. Lazic, S.E.; Clarke-Williams, C.J.; Munafo, M.R. What exactly is 'N' in cell culture and animal experiments? *PLoS Biol.* **2018**, *16*, e2005282. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.